4'-Ethoxyuridin | 70228-72-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4'-Ethoxyuridin
• 英文别名: 4'-ethoxy-uridine；1-[(2R,3R,4S,5R)-5-ethoxy-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 70228-72-7
• 化学式: C₁₁H₁₆N₂O₇
• 分子量: 288.257
• InChiKey: XXXNOGYPJKXISH-PKIKSRDPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] NUCLÉOSIDES 4'-OR POUR LE TRAITEMENT DU VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015095419A1

  公开（公告）日：2015-06-25

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4'-OR nucleosides of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.

  本文提供了用于治疗黄病毒科感染的化合物、组合物和方法，包括HCV感染。在某些实施方式中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。在某些实施方式中，所述化合物是公式I的4'-OR核苷衍生物：(I)；或其在药学上可接受的盐，其中Base、PD、R、Z1、Z2、Z3和Z4如本文所定义。
• 4′-or nucleosides for the treatment of HCV
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：US10683321B2

  公开（公告）日：2020-06-16

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4′-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.

  本文提供了用于治疗黄病毒科感染（包括 HCV 感染）的化合物、组合物和方法。在某些实施方案中，公开了核苷衍生物的化合物和组合物，可单独或与其他抗病毒药物联合使用。在某些实施方案中，化合物是式 I 的 4′-OR 核苷： 或其药学上可接受的盐，其中 Base、PD、R、Z1、Z2、Z3 和 Z4 如本文所定义。
• 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：US20180162898A1

  公开（公告）日：2018-06-14

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4′-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z 1 , Z 2 , Z 3 , and Z 4 are as defined herein.